Stocktwits on MSN
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum
The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. ・CEO Angelos ...
Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia. ・Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the ...
A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have ...
SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results